Vyome Holdings (HIND) Preferred Stock Liabilities (2015 - 2016)
Vyome Holdings (HIND) posted quarterly Preferred Stock Liabilities of $70.5 million for Q3 2016, up 28.88% quarter-over-quarter from $54.7 million in Q4 2015.
Vyome Holdings (HIND) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Vyome Holdings' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $70.5 million for Q3 2016.
- In Q3 2016, Preferred Stock Liabilities changed N/A year-over-year to $70.5 million; the TTM figure through Sep 2016 stood at $70.5 million (changed N/A YoY), while the FY2015 annual figure was $54.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2016 stood at $70.5 million, up from $54.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $70.5 million in Q3 2016, with the low at $54.7 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 70.50 Mn |
| Dec 31, 2015 | 54.70 Mn |